Evidence map›Paper›PMID 26466826›Full record

ReviewBritish journal of clinical pharmacology2016

Achieving the World Health Organization's vision for clinical pharmacology.

Jennifer H Martin, David Henry, Jean Gray, Richard Day, Felix Bochner, Albert Ferro, Munir Pirmohamed, Klaus Mörike, Matthias Schwab

Open access · bronzeAbstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Parasitic pharmacology: A plausible mechanism of action for cannabidiol.British journal of clinical pharmacology · 2020
    Article
  7. Review
  8. Article
  9. Modelling Medications for Public Health Research.Online journal of public health informatics · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 6 countries.

Jennifer H MartinDiscipline of Clinical Pharmacology, University of Newcastle, Australia.
David HenryInstitute for Clinical Evaluative Sciences and University of Toronto, Toronto.
Jean GrayDalhousie University Faculty of Medicine, Halifax, Canada.
Richard DayClinical Pharmacology, St Vincent's Hospital Clinical School and Pharmacology, School of Medical Sciences, Faculty of Medicine, UNSW, Sydney.
Felix BochnerThe University of Adelaide, Royal Adelaide Hospital, South Australia, Australia.
Albert FerroDepartment of Clinical Pharmacology, Kings College London.
Munir PirmohamedThe Wolfson Centre for Personalized Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom.
Klaus MörikeDepartment Clinical Pharmacology, University Hospital Tübingen, Germany.
Matthias SchwabDepartment Clinical Pharmacology, University Hospital Tübingen, Germany.
University Children's Hospital Tübingen · DEDalhousie University · CAInstitute for Clinical Evaluative Sciences · CAKing's College - North Carolina · USSt Vincent's Clinic · AUUniversity of Adelaide · AUUniversity of Liverpool · GBUniversity of Newcastle Australia · AU

Funding

Medical Research Council G0700654Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Clinical pharmacology is a medical specialty whose practitioners teach, undertake research, frame policy, give information and advice about the actions and proper uses of medicines in humans and implement that knowledge in clinical practice. It involves a combination of several activities: drug discovery and development, training safe prescribers, providing objective and evidence-based therapeutic information to ethics, regulatory and pricing bodies, supporting patient care in an increasingly subspecialized arena where co-morbidities, polypharmacy, altered pharmacokinetics and drug interactions are common and developing and contributing to medicines policies for Governments. Clinical pharmacologists must advocate drug quality and they must also advocate for sustainability of the Discipline. However for this they need appropriate clinical service and training support. This Commentary discusses strategies to ensure the Discipline is supported by teaching, training and policy organizations, to communicate the full benefits of clinical pharmacology services, put a monetary value on clinical pharmacology services and to grow the clinical pharmacology workforce to support a growing clinical, academic and regulatory need.

Indexed as

Practice Guidelines as TopicHumansPatient-Centered CarePharmacology, ClinicalPharmacy Service, HospitalWorkforceWorld Health Organizationclinical pharmacologyhealth workforceleadership

Identifiers

PMID26466826
PMCPMC4833156
OpenAlexW2175982225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.